Company Encyclopedia
View More
name
Panlong Pharmaceutical
002864.SZ
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chinese medicine anti-inflammatory products. The company was founded in 1997 and is based in Xi'an, China.
3.159 T
002864.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking65/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.32%B
    • Profit Margin10.97%B
    • Gross Margin56.20%B
  • Growth ScoreB
    • Revenue YoY11.91%B
    • Net Profit YoY3.97%C
    • Total Assets YoY6.38%B
    • Net Assets YoY4.75%B
  • Cash ScoreB
    • Cash Flow Margin911.49%B
    • OCF YoY11.91%B
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreB
    • Gearing Ratio29.79%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhitong A-share lock-up release overview | November 4

    On November 4th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 157 million yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Changchun Gaoxin 000661 Equity Incentive Restricted Circulation 42,900 Yunnai Power 000903 Equity Incentive Restricted Circulation 14,978,800 YIWU CCC 600415 Equity Incentive Restricted Circulation 795,600 Valiant 002643 Equity Incentive Restricted Circulation 7,128,800 Panlong Pharmaceutical 002864 Equity Incentive Restricted Circulation 281,600

    Zhitong·
    SH
    600415
    +1.30%
    SZ
    002643
    +0.93%
    SZ
    002864
    -2.02%
    Zhitong·
    SH
    600415
    +1.30%
    SZ
    002643
    +0.93%
    SZ
    002864
    -2.02%

    Panlong Pharmaceutical: The net profit for the third quarter was 29.6707 million yuan, a decrease of 0.83%

    Panlong Pharmaceutical announced that its revenue for the third quarter was 267 million yuan, a year-on-year increase of 2.24%; net profit was 29.6707 million yuan, a decrease of 0.83%. Revenue for the first three quarters was 841 million yuan, a year-on-year increase of 17.37%; net profit was 89.8059 million yuan, an increase of 0.26%

    Zhitong·
    SZ
    002864
    -2.02%
    Zhitong·
    SZ
    002864
    -2.02%

    Panlong Pharmaceutical: The company currently has no overseas sales business

    On September 29th, Panlong Pharmaceutical stated on the interactive platform that the company currently has no overseas sales business

    Zhitong·
    SZ
    002864
    -2.02%
    Zhitong·
    SZ
    002864
    -2.02%

    Panlong Pharmaceutical: PLJT-001 Loxoprofen Sodium Gel Patch has received the acceptance notice for domestic drug production registration and marketing license

    Panlong Pharmaceutical recently announced that its research and development product, Loxoprofen Sodium Gel Patch (PLJT-001), has received the acceptance notice for the marketing authorization application from the National Medical Products Administration. This product is used to treat osteoarthritis, muscle pain, and swelling or pain after injury, with significant anti-inflammatory and analgesic effects, as well as low irritation and good skin compatibility, enhancing the comfort and convenience of medication

    Zhitong·
    SZ
    002864
    -2.02%
    Zhitong·
    SZ
    002864
    -2.02%

    Panlong Pharmaceutical: In the first half of 2025, the net profit was 60.1352 million yuan, a year-on-year increase of 0.81%

    Panlong Pharmaceutical announced that in the first half of 2025, the operating revenue was 574 million yuan, a year-on-year increase of 26.06%. The net profit was 60.1352 million yuan, a year-on-year increase of 0.81%. The company plans to distribute a cash dividend of 1 yuan for every 10 shares based on a total of 106 million shares to all shareholders

    Zhitong·
    SZ
    002864
    -2.02%
    Zhitong·
    SZ
    002864
    -2.02%
    © 2025 Longbridge｜Disclaimer